Correlation Between Marizyme and Defence Therapeutics
Can any of the company-specific risk be diversified away by investing in both Marizyme and Defence Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Marizyme and Defence Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Marizyme and Defence Therapeutics, you can compare the effects of market volatilities on Marizyme and Defence Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Marizyme with a short position of Defence Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Marizyme and Defence Therapeutics.
Diversification Opportunities for Marizyme and Defence Therapeutics
0.35 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Marizyme and Defence is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Marizyme and Defence Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Defence Therapeutics and Marizyme is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Marizyme are associated (or correlated) with Defence Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Defence Therapeutics has no effect on the direction of Marizyme i.e., Marizyme and Defence Therapeutics go up and down completely randomly.
Pair Corralation between Marizyme and Defence Therapeutics
Given the investment horizon of 90 days Marizyme is expected to generate 21.91 times more return on investment than Defence Therapeutics. However, Marizyme is 21.91 times more volatile than Defence Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Defence Therapeutics is currently generating about -0.14 per unit of risk. If you would invest 4.00 in Marizyme on September 19, 2024 and sell it today you would lose (1.80) from holding Marizyme or give up 45.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 97.62% |
| Values | Daily Returns |
Marizyme vs. Defence Therapeutics
Performance |
| Timeline |
| Marizyme |
| Defence Therapeutics |
Marizyme and Defence Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Marizyme and Defence Therapeutics
The main advantage of trading using opposite Marizyme and Defence Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Marizyme position performs unexpectedly, Defence Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Defence Therapeutics will offset losses from the drop in Defence Therapeutics' long position.| Marizyme vs. Deere Company | Marizyme vs. Caterpillar | Marizyme vs. Lion Electric Corp | Marizyme vs. Nikola Corp |
| Defence Therapeutics vs. Aileron Therapeutics | Defence Therapeutics vs. Enlivex Therapeutics | Defence Therapeutics vs. Living Cell Technologies | Defence Therapeutics vs. Multicell Techs |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Complementary Tools
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |